The hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) is rarely curable despite availability of current treatment paradigm. The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are rapidly transforming the care of patients with (HR+/HER2−) ABC.1 In this regard, Novartis and Docplexus have organized an interactive webinar on 20th November 2021 from 7.00 PM IST onwards. In this webinar, our renowned international experts Dr. Aditya Bardia and Dr. Priscilla B.
Caguioa will discuss the latest updates in HR+/HER2- advanced breast cancer and the role of CDK4/6 inhibitors in its treatment. Reference: Shah M, Nunes MR, Stearns V. Oncology (Williston Park). 2018;32(5):216-222.